In contrast, B-cell malignancies are less sensitive to PD-1 block-
1. Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010;42(2):181-185.
2. Bodor C, O'Riain C, Wrench D, et al. EZH2 Y641 mutations in follicular lymphoma. Leukemia. 2011;25(4):726-729.
3. Ryan RJ, Nitta M, Borger D, et al. EZH2 codon 641 mutations are
common in BCL2-rearranged germinal center B cell lymphomas.
PLoS One. 2011;6(12):e28585.
4. Visser HP, Gunster MJ, Kluin-N elemans HC, et al. The Polycomb
group protein EZH2 is upregulated in proliferating, cultured
human mantle cell lymphoma. Br J Haematol. 2001;112(4):
950-958.
5. Zhang X, Zhao X, Fiskus W, et al. Coordinated silencing of MYC-
mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of
histone modification in aggressive B-Cell lymphomas. Cancer Cell.
2012;22(4):506-523.
ade therapy,50,51 which could be partly explained by the scarcity of
tumor-infiltrating T cells that can readily exert antitumor immune responses.52-54 Our findings suggest that an EZH2 inhibitor can induce
T-cell inflamed lymphoma microenvironment and is expected to be
utilized for amplifying the effect of immunotherapy.
We observed CCL17 upregulation by tazemetostat in all 11 B-cell
lymphoma lines tested, irrespective of their histologic origin. In the
analysis of FL and GCB-DLBCL databases, CCL17 expression levels
were shown to significantly inversely parallel the EZH2-activated
signature and positively correlate with both CD4+ and CD8+ T-cell
signatures. On the other hand, the association among CCL17 expression levels, EZH2-activated signature, and T-cell signatures was
YUAN et al.
6. Knutson SK, Wigle TJ, Warholic NM, et al. A selective inhibitor of
EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
Nat Chem Biol. 2012;8(11):890-896.
7. McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature.
2012;492(7427):108-112.
8. Italiano A, Soria JC, Toulmonde M, et al. Tazemetostat, an EZH2
inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma
and advanced solid tumours: a first-in-human, open-label, phase 1
study. Lancet Oncol. 2018;19(5):649-659.
9. Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for
patients with relapsed or refractory follicular lymphoma: an
open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol.
2020;21(11):1433-1442.
10. Munakata W, Shirasugi Y, Tobinai K, et al. Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma. Cancer Sci. 2021;112(3):1123-1131.
11. Kuppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer.
2009;9(1):15-27.
12. Steidl C, Diepstra A, Lee T, et al. Gene expression profiling of
microdissected Hodgkin Reed-Sternberg cells correlates with
treatment outcome in classical Hodgkin lymphoma. Blood.
2012;120(17):3530-3540.
13. Ono SJ, Nakamura T, Miyazaki D, Ohbayashi M, Dawson M, Toda M.
Chemokines: roles in leukocyte development, trafficking, and effector function. J Allergy Clin Immunol. 2003;111(6):1185-1199. quiz 200.
14. Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin:
mechanisms and clinical consequences. Nat Rev Immunol.
2004;4(3):211-222.
15. Maesako Y, Uchiyama T, Ohno H. Comparison of gene expression
profiles of lymphoma cell lines from transformed follicular lymphoma, Burkitt's lymphoma and de novo diffuse large B-cell lymphoma. Cancer Sci. 2003;94(9):774-781.
16. Epstein AL, Levy R, Kim H, Henle W, Henle G, Kaplan HS. Biology
of the human malignant lymphomas. IV. Functional characterization of ten diffuse histiocytic lymphoma cell lines. Cancer.
1978;42(5):2379-2391.
17. Nozawa Y, Abe M, Wakasa H, et al. Establishment and characterization of an Epstein-Barr virus negative B-cell lymphoma cell
line and successful heterotransplantation. Tohoku J Exp Med.
1988;156(4):319-330.
18. Pulvertaft JV. Cytology of Burkitt's tumour (African Lymphoma).
Lancet. 1964;1(7327):238-240.
19. Klein E, Klein G, Nadkarni JS, Nadkarni JJ, Wigzell H, Clifford P.
Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo
and in derived culture lines. Cancer Res. 1968;28(7):1300-1310.
20. Jadayel DM, Lukas J, Nacheva E, et al. Potential role for concurrent
abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes
in certain B cell non-Hodgkin's lymphomas. Functional studies in a
cell line (Granta 519). Leukemia. 1997;11(1):64-72.
21. Nishikori M, Maesako Y, Ueda C, Kurata M, Uchiyama T, Ohno
H. High-level expression of BCL3 differentiates t(2;5)(p23;q35)-
positive anaplastic large cell lymphoma from Hodgkin disease.
Blood. 2003;101(7):2789-2796.
22. Kadowaki N, Ho S, Antonenko S, et al. Subsets of human dendritic
cell precursors express different toll-like receptors and respond to
different microbial antigens. J Exp Med. 2001;194(6):863-869.
23. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA.
2005;102(43):15545-15550.
24. Lee TI, Johnstone SE, Young RA. Chromatin immunoprecipitation
and microarray-based analysis of protein location. Nat Protoc.
2006;1(2):729-748.
4615
25. Miyara M, Yoshioka Y, Kitoh A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3
transcription factor. Immunity. 2009;30(6):899-911.
26. Reddy A, Zhang J, Davis NS, et al. Genetic and functional drivers of
diffuse large B cell lymphoma. Cell. 2017;171(2):481-94 e15.
27. Richter J, Schlesner M, Hoffmann S, et al. Recurrent mutation
of the ID3 gene in Burkitt lymphoma identified by integrated
genome, exome and transcriptome sequencing. Nat Genet.
2012;44(12):1316-1320.
28. Shaffer AL, Wright G, Yang L, et al. A library of gene expression
signatures to illuminate normal and pathological lymphoid biology.
Immunol Rev. 2006;210:67-85.
29. Beguelin W, Popovic R, Teater M, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 2013;23(5):677-692.
3 0. Ott HM, Graves AP, Pappalardi MB, et al. A687V EZH2 is a driver of
histone H3 lysine 27 (H3K27) hypertrimethylation. Mol Cancer Ther.
2014;13(12):3062-3 073.
31. Otsuka Y, Nishikori M, Arima H, et al. EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas. Mol
Immunol. 2020;119:35-45.
32. Kanzler H, Küppers R, Hansmann ML, Rajewsky K. Hodgkin and
Reed-Sternberg cells in Hodgkin's disease represent the outgrowth
of a dominant tumor clone derived from (crippled) germinal center
B cells. J Exp Med. 1996;184(4):1495-1505.
33. Marafioti T, Hummel M, Foss HD, et al. Hodgkin and reed-sternberg
cells represent an expansion of a single clone originating from a
germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood.
2000;95(4):1443-1450.
3 4. Pastore A, Jurinovic V, Kridel R, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis
of a prospective clinical trial and validation in a population-based
registry. Lancet Oncol. 2015;16(9):1111-1122.
35. Bracken AP, Helin K. Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat Rev Cancer. 2009;9(11):
773-784.
36. Rui L, Emre NC, Kruhlak MJ, et al. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell. 2010;18(6):590-605.
37. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with
nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J
Med. 2015;372(4):311-319.
38. Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic hodgkin lymphoma after failure of autologous
hematopoietic cell transplantation: extended follow-up of the
multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol.
2018;36(14):1428-1439.
39. Chen R, Zinzani PL, Fanale MA, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic
Hodgkin lymphoma. J Clin Oncol. 2017;35(19):2125-2132.
4 0. Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of
Hodgkin's lymphoma: increasing evidence of the importance of the
microenvironment. J Clin Oncol. 2011;29(14):1812-1826.
41. Yoshida M, Ichikawa A, Miyoshi H, et al. High frequency of t(14;18)
in Hodgkin's lymphoma associated with follicular lymphoma. Pathol
Int. 2012;62(8):518-524.
42. Küppers R, Dührsen U, Hansmann ML. Pathogenesis, diagnosis, and
treatment of composite lymphomas. Lancet Oncol. 2014;15(10):e43
5-e 446.
43. Bräuninger A, Hansmann ML, Strickler JG, et al. Identification of
common germinal-center B-cell precursors in two patients with
both Hodgkin's disease and non-Hodgkin's lymphoma. N Engl J Med.
1999;340(16):1239-1247.
4616 4 4. Huang Q, Wilczynski SP, Chang KL, Weiss LM. Composite recurrent
hodgkin lymphoma and diffuse large B-cell lymphoma: one clone,
two faces. Am J Clin Pathol. 2006;126(2):222-229.
45. Küppers R, Sousa AB, Baur AS, Strickler JG, Rajewsky K, Hansmann
ML. Common germinal-center B-cell origin of the malignant cells in
two composite lymphomas, involving classical Hodgkin's disease and
either follicular lymphoma or B-CLL. Mol Med. 2001;7(5):285-292.
46. Marafioti T, Hummel M, Anagnostopoulos I, Foss HD, Huhn D,
Stein H. Classical Hodgkin's disease and follicular lymphoma
originating from the same germinal center B cell. J Clin Oncol.
1999;17(12):3804-3809.
47. Nakamura N, Ohshima K, Abe M, Osamura Y. Demonstration of
chimeric DNA of bcl-2 and immunoglobulin heavy chain in follicular
lymphoma and subsequent Hodgkin lymphoma from the same patient. J Clin Exp Hematop. 2007;47(1):9-13.
48. Rosenquist R, Roos G, Erlanson M, Küppers R, Bräuninger A,
Hansmann ML. Clonally related splenic marginal zone lymphoma
and Hodgkin lymphoma with unmutated V gene rearrangements and a 15-yr time gap between diagnoses. Eur J Haematol.
2004;73(3):210-214.
49. van den Berg A, Maggio E, Rust R, Kooistra K, Diepstra A, Poppema
S. Clonal relation in a case of CLL, ALCL, and Hodgkin composite
lymphoma. Blood. 2002;100(4):1425-1429.
50. Ansell SM, Minnema MC, Johnson P, et al. Nivolumab for relapsed/
refractory diffuse large B-cell lymphoma in patients ineligible for
or having failed autologous transplantation: a single-arm. Phase II
Study. J Clin Oncol. 2019;37(6):481-489.
YUAN et al.
51. Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients
with relapsed or refractory hematologic malignancy: preliminary
results of a phase Ib study. J Clin Oncol. 2016;34(23):2698-2704.
52. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces
responses by inhibiting adaptive immune resistance. Nature.
2014;515(7528):568-571.
53. Chen PL, Roh W, Reuben A, et al. Analysis of immune signatures
in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 2016;6(8):827-837.
54. Salmon H, Remark R, Gnjatic S, Merad M. Host tissue determinants
of tumour immunity. Nat Rev Cancer. 2019;19(4):215-227.
S U P P O R T I N G I N FO R M AT I O N
Additional supporting information may be found online in the
Supporting Information section.
How to cite this article: Yuan H, Nishikori M, Otsuka Y, Arima
H, Kitawaki T, Takaori-Kondo A. The EZH2 inhibitor
tazemetostat upregulates the expression of CCL17/TARC in
B-cell lymphoma and enhances T-cell recruitment. Cancer Sci.
2021;112:4604–4616. https://doi.org/10.1111/cas.15122
...
論文の公開元へ
